James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., de Bono, J., Cross, W., Jones, R. J., Thalmann, G., Amos, C., Matheson, D., Millman, R., Alzouebi, M., Beesley, S., Birtle, A. J., Brock, S., Cathomas, R., Chakraborti, P., Chowdhury, S., Cook, A., Elliott, T., Gale, J., Gibbs, S., Graham, J. D., Hetherington, J., Hughes, R., Laing, R., McKinna, F., McLaren, D. B., O'Sullivan, J. M., Parikh, O., Peedell, C., Protheroe, A., Robinson, A. J., Srihari, N., Srinivasan, R., Staffurth, J., Sundar, S., Tolan, S., Tsang, D., Wagstaff, J., Parmar, M. K. B., & , (2016). addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), 1163–1177. http://access.bl.uk/ark:/81055/vdc_100031152364.0x00001c